Appili Therapeutics develops novel antibiotic and anti‑infective therapies targeting serious infections and the increasing resistance to currently available antibiotics. Its pipeline includes ATI‑1701, an in‑licensed tularemia vaccine; ATI‑1503, a negamycin‑analogue antibiotic discovery program; and ATI‑1501, a taste‑masked oral‑suspension formulation of metronidazole. The company is headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, and pursues worldwide opportunities with science and industry partners, governments and agencies. Appili says it will use recent assistance to procure materials for continued development of its pipeline and to further explore listing its common shares on the TSX Venture Exchange. The firm recently raised $3.6 million CAD in a private placement and has received additional government support to maintain highly qualified positions and world‑class R&D operations in Halifax. Management framed the work as addressing urgent global public‑health threats from antimicrobial resistance. Appili Therapeutics focuses on developing and commercializing anti-infective drugs, balancing near-to-market candidates with higher-risk early-stage programs. Its pipeline includes ATI-1501, a taste-masked oral suspension formulation of metronidazole for pediatric and elderly patients, and ATI-1503, a drug discovery program for negamycin analogues targeting Gram-negative bacteria. Via in-licensing, Appili acquired ATI-1701, a tularemia vaccine intended to remove risk from a weaponized pathogen. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, the company pursues worldwide opportunities with science and industry partners and government agencies. Financially, Appili raised an additional $4,339,000 in an oversubscribed private placement and is receiving a $500,000 repayable contribution from the Government of Canada, bringing total equity raised since its March 2016 seed round to $11,816,000. Proceeds will fund operations, continued growth, and expansion of the pipeline through further in-licensing. Appili Therapeutics is an anti-infective drug development company based in Halifax, Nova Scotia. The company has two programs, ATI-1501 and ATI-1503, targeting anaerobic and Gram-negative infections respectively. ATI-1501 is a taste-masked treatment for anaerobic infections that has been granted orphan drug status by the FDA. Appili planned to take ATI-1501 into clinical trials in 2017. ATI-1503 is described as a novel antibiotic with potential to treat deadly Gram-negative, drug-resistant infections. The company raised additional equity to support operations and advance its pipeline. Appili Therapeutics is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs in its pipeline: ATI-1501, a taste-masked treatment for anaerobic infections including C. difficile, and ATI-1503, a novel antibiotic aimed at drug-resistant Gram-negative infections. ATI-1503 is a synthetic version of the naturally occurring Negamycin antibiotic and is reported to penetrate double bacterial membranes to attack the protein-generating machinery of Gram-negative bacteria. Appili plans to use advanced X-ray crystallography to visualize ATI-1503 binding to its bacterial target and systematically optimize potency. Financially, Appili announced additional support from the Government of Canada’s NRC-IRAP—an extra $400,000 that brings IRAP support for this project to up to $759,000. The company’s CFO said IRAP funding is an important part of Appili’s financial strategy for developing a new antibiotic to treat deadly, drug-resistant infections. Appili Therapeutics is developing reformulated and novel antibiotics to treat serious infectious diseases. Its lead program, ATI-1501, is a taste-masked oral reformulation of metronidazole intended to treat anaerobic infections including Clostridium difficile. The company is manufacturing a clinical batch of ATI-1501 to good manufacturing practices (GMP) and plans to take the drug into human clinical trials this year. ATI-1501 has been optimized to improve palatability and patient compliance, addressing problems with bitter-tasting metronidazole tablets in children and the elderly. Appili’s pipeline also includes ATI-1503, a novel antibiotic targeting deadly Gram-negative infections such as Klebsiella pneumoniae. The company is positioning ATI-1501 for market approval pending successful clinical trials.

Total raised

$17M

Funding rounds

8

Latest round

Debt Financing

Latest activity

Apr 2019